BONTRIL PDM CIII
Generic Name and Formulations:
Phendimetrazine tartrate 35mg; scored tabs.
Valeant Pharmaceuticals, Inc
Indications for BONTRIL PDM:
Short-term adjunct in managing exogenous obesity.
35mg 2 or 3 times daily, 1 hour before meals; may reduce to 17.5mg/dose. Max 210mg/day in 3 evenly divided doses.
Advanced arteriosclerosis. Cardiovascular disease. Moderate or severe hypertension. Hyperthyroidism. Glaucoma. Highly nervous or agitated states. Drug or alcohol abuse. Concomitant CNS stimulants. During or within 14 days of MAOIs (see Interactions).
Discontinue after a few weeks as tolerance to anorectic effect occurs. Avoid abrupt cessation after prolonged high doses. Mild hypertension. Abuse and dependence potential. Diabetes. Reevaluate after drug-free interval. Prescribe minimal supply to avoid overdose. Pregnancy.
Hypertensive crisis with MAOIs. May antagonize guanethidine. CNS effects with alcohol, other CNS drugs.
Palpitation, tachycardia, hypertension, CNS overstimulation, dry mouth, GI disturbances, urinary frequency, changes in libido.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine